Literature DB >> 11399224

Approaches to gene therapy for human immunodeficiency virus infection.

G L Buchschacher1, F Wong-Staal.   

Abstract

Much progress has been made in developing new and more efficient treatments for human immunodeficiency virus (HIV) infection, the cause of acquired immunodeficiency syndrome (AIDS). However, the scope of the HIV epidemic and the limitations of existing treatments necessitate the continued development of novel treatment strategies. Gene therapy is one such forward-looking strategy. Gene therapy approaches for HIV infection include efforts to interfere with viral replication directly by engineering HIV-resistant cells or indirectly by eliminating infected cells from the body, primarily by eliciting a therapeutic immune response to destroy HIV-infected cells. Although the prospect of gene therapy as a routine treatment for HIV infection remains distant, continuous progress is being made, which should also have implications for gene therapy strategies for a variety of other diseases. This article reviews some of the strategies for investigating the feasibility of gene transfer for the treatment of HIV infection.

Entities:  

Mesh:

Year:  2001        PMID: 11399224     DOI: 10.1089/104303401750214249

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments.

Authors:  Dahai Jiang; Aliasger K Salem
Journal:  Int J Pharm       Date:  2011-10-21       Impact factor: 5.875

Review 3.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

4.  Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells.

Authors:  Camille Lévy; Fouzia Amirache; Caroline Costa; Cecilia Frecha; Claude P Muller; Hasan Kweder; Robin Buckland; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

5.  Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.

Authors:  Ornellie Bernadin; Fouzia Amirache; Anais Girard-Gagnepain; Ranjita Devi Moirangthem; Camille Lévy; Kuiying Ma; Caroline Costa; Didier Nègre; Christian Reimann; David Fenard; Agata Cieslak; Vahid Asnafi; Hanem Sadek; Rana Mhaidly; Marina Cavazzana; Chantal Lagresle-Peyrou; François-Loïc Cosset; Isabelle André; Els Verhoeyen
Journal:  Blood Adv       Date:  2019-02-12

6.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

7.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes.

Authors:  Vladimir P Torchilin; Tatyana S Levchenko; Ram Rammohan; Natalia Volodina; Brigitte Papahadjopoulos-Sternberg; Gerard G M D'Souza
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

8.  Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.

Authors:  Grant D Trobridge; Robert A Wu; Brian C Beard; Sum Ying Chiu; Nina M Muñoz; Dorothee von Laer; John J Rossi; Hans-Peter Kiem
Journal:  PLoS One       Date:  2009-11-02       Impact factor: 3.240

Review 9.  Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy.

Authors:  Alejandra Gutierrez-Guerrero; François-Loïc Cosset; Els Verhoeyen
Journal:  Viruses       Date:  2020-09-11       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.